Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

638.88 -3.71 (-0.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
62 63 Next >
News headline image
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Where Will Regeneron Pharmaceuticals Be in 1 Year? ↗
Can the stock continue its market-beating ways? 
Via The Motley Fool
News headline image
7 Undervalued Nasdaq-100 Stocks for Bargain Hunters ↗
Though tech innovators blossomed this year, you can still find undervalued deals. 
Via InvestorPlace
News headline image
$1000 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
It's Almost 2024: 3 Top Stocks to Buy Before the New Year ↗
You can pick these players up for a great price right now. 
Via The Motley Fool
News headline image
AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
3 Stocks to Buy Before 2024 That Can Set You Up For Life ↗
These stocks are still relatively cheap, but don't expect them to stay that way for long. 
Via The Motley Fool
News headline image
Reasonable growth and debt and a high ROIC for REGENERON PHARMACEUTICALS (NASDAQ:REGN). ↗
Exploring REGENERON PHARMACEUTICALS (NASDAQ:REGN)'s quality characteristics. 
Via Chartmill
News headline image
3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
News headline image
11 Analysts Have This to Say About Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Biotech Is Coming Back, Can The Run Last? ↗
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
News headline image
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
News headline image
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire? ↗
Regeneron has been an excellent investment in recent years. Can that trend continue? 
Via The Motley Fool
News headline image
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise ↗
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
News headline image
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
News headline image
GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places ↗
The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500. 
Via InvestorPlace
Topics Stocks
News headline image
$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Biotech And Healthcare Portfolio Playbook For December 2023/24 ↗
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
News headline image
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales ↗
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation. 
Via Investor's Business Daily
News headline image
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.